A novel and effective intranasal immunization strategy for respiratory syncytial virus.

In designing subunit vaccination strategies for respiratory syncytial virus (RSV), immunization by mucosal routes may present a realistic alternative to parenteral administration for inducing protective immune responses. To this end, we have utilized the BALB/c mouse model and an adjuvant formulation containing caprylic/capric glycerides (CCG) and polyoxyethylene-20-sorbitan monolaurate (PS). The intranasal (i.n.) delivery of purified natural F protein (3 microg per vaccine) formulated with CCG-PS resulted in the generation of statistically heightened serum anti-F protein immunoglobulin G (IgG), IgG1, IgG2b, and IgA antibodies. In addition, the presence of locally produced anti-F protein IgA was demonstrated in both vaginal and nasal washes of vaccinated mice. That production of specific serum and mucosal immunoglobulins resulted in functional immune responses was shown in neutralizing antibody assays and protection of mouse lungs against subsequent live virus challenge. Consequently, we propose a novel vaccine formulation composed of purified natural RSV F protein in CCG-PS as a viable intranasal immunogen to stimulate anti-RSV immune responses in humans.

[1]  J. Eldridge,et al.  Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H. , 2000, Vaccine.

[2]  N. Meanwell,et al.  Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents. , 2000, Drug discovery today.

[3]  B. Graham,et al.  Priming with Secreted Glycoprotein G of Respiratory Syncytial Virus (RSV) Augments Interleukin-5 Production and Tissue Eosinophilia after RSV Challenge , 1998, Journal of Virology.

[4]  R. Welliver,et al.  Respiratory syncytial virus affects pulmonary function in BALB/c mice. , 1998, The Journal of infectious diseases.

[5]  H. Hansen,et al.  Absorption and metabolism of the absorption enhancer didecanoylphosphatidylcholine in rabbit nasal epithelium in vivo. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[6]  S. Gizurarson,et al.  Intranasal booster vaccination against diphtheria and tetanus in man. , 1997, Vaccine.

[7]  H. Valdimarsson,et al.  Intranasal vaccination against diphtheria and tetanus in human subjects , 1997 .

[8]  S. Gizurarson,et al.  Intranasal vaccination against influenza using pharmaceutical excipients as immunological adjuvants , 1996 .

[9]  A. Almeida,et al.  Nasal delivery of vaccines. , 1996, Journal of drug targeting.

[10]  R. Baggs,et al.  Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. , 1995, Vaccine.

[11]  S. Gizurarson,et al.  Intranasal administration of diphtheria toxoid. Selecting antibody isotypes using formulations having various lipophilic characteristics. , 1995, Vaccine.

[12]  S. Pillai,et al.  The pulmonary immune response of Balb/c mice vaccinated with the fusion protein of respiratory syncytial virus. , 1994, Vaccine.

[13]  E. Walsh,et al.  Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. , 1994, Vaccine.

[14]  E. Walsh.  Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice. , 1993, Vaccine.

[15]  R. Chanock,et al.  Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. , 1992, Pediatrics.

[16]  R. Chanock,et al.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.